Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ALA-1000 in Opioid-Dependent Individuals
NCT04122755Phase 1Completed
- Sponsor
- Alar Pharmaceuticals Inc.
- Start
- Sep 2019
- Primary completion
- May 2021
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ALA-1000 in opioid use disorder (OUD) (6 cohorts), sponsored by Alar Pharmaceuticals Inc. Primary endpoints: Incidence of Adverse Events at Day 175, Change in Vital Signs at Day 175 and 4 more. Started Sep 2019; status: completed.
02
Drugs
ALA-1000
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT04122755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04122755.